Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLarge granular lymphocytosis during dasatinib therapyOff-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsDasatinib promotes Th1-type responses in granzyme B expressing T-cellsAnalysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaBiological therapy and the immune system in patients with chronic myeloid leukemia.Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Immunology and immunotherapy of chronic myeloid leukemia.Targeting Fyn Kinase in Alzheimer's Disease.Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug.Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children.CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway.The potential of Src inhibitors.Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.Cytomegalovirus pulls strings behind NK cells.The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.Detection of leukemia associated antigen-specific cytotoxic T cells in a patient with Philadelphia chromosome-positive leukemia during treatment with dasatinib.Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.Spectrum of Clonal Large Granular Lymphocytes (LGLs) of αβ T Cells: T-Cell Clones of Undetermined Significance, T-Cell LGL Leukemias, and T-Cell Immunoclones.Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review.
P2860
Q26749324-C9215B98-F7A3-4514-8866-6331BFF76EFEQ27012699-4E834462-FAC7-4C6F-81AC-33C79AFF4A8DQ33401360-EDC403D3-FCA9-479A-99BD-5C45A0A9AF6EQ33404602-13537AC3-641A-48BF-9481-4B745CCEFC62Q33798573-FCDCBF79-C025-494D-9257-A19C006FCFC9Q33930605-9A084ED2-8CCD-4D58-924F-D55DD6610012Q35889240-17034897-0688-4699-87D1-42937A4C4280Q35914856-DE74A87A-7FF3-4F6C-A9C2-87C527CF1907Q37098840-0A2D98A3-DD77-4078-AABB-4E80292D1BC6Q37702242-CF13353E-0A74-4B3A-8850-610E24455481Q38015742-CC30E634-62BB-4839-B374-9D6EBC396B2EQ38095771-087C97D3-5BC6-46C7-93D3-CBEC419EBEA0Q38128723-1DF20D71-AE67-4F75-8277-D705182F164EQ38175864-C274FA6E-996C-4655-8EBA-788061FD2F62Q38678555-E3443AEC-0016-4465-B2C7-3D98643F502FQ39168624-BB73E3D7-110B-4D35-A865-25FD152A4EF4Q39379461-5F186D81-E1E5-41B2-A9BB-895BD5EAF8B4Q40643461-5C9911DF-531A-42A2-AB77-2589881716FEQ40679442-54A733BA-34B3-4BCB-811F-79BD6EB0E25DQ41356321-DD3E0C15-4716-4CB0-8647-1DF83DC7E028Q41661752-6606F66D-499D-4F42-AA6A-B20FE0BAAB34Q41767329-FDBB7E57-8264-4648-843C-64AC4274CE5EQ42226854-018A6420-01E2-40FA-ADD2-0C3B58CF1E54Q42373318-F81BF042-AB88-47BE-8420-81656EB86C7BQ43184281-0203C899-103F-4884-A10D-4C424D3429B3Q44222188-A730A743-2459-4C5A-96B0-A832D8605BFEQ44679459-8971ACA6-17EE-42CF-AF44-0D98D372E439Q44690584-76B98D98-AC25-4DAB-A3D2-8E0A32DE7518Q47095637-425749B7-29F8-4177-89D1-B288898C0B1CQ48147441-F073656E-1668-4CE0-A76C-6BEC14696730Q49276933-B354940B-51F7-4193-BD7D-B6E1DDA6E91AQ49291505-8ABA8EA6-AAE8-463B-8A80-9FE74DCA465DQ50927763-766BF348-5E99-443E-B997-38277177A10CQ53215863-B182C1CD-7C4A-4DB9-A005-472159A5AF7DQ53469461-6180CE09-C9AE-491A-A2D9-268858E9585EQ54499425-057211D8-FD6E-4469-9A11-451C405EAE7DQ54539122-5E11DFE9-80E9-4FCF-96CC-CEC4C4E2DBE8Q55446905-A4C2CA36-3DD3-492E-BBBB-EC3AD60AF4EA
P2860
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Expansion of highly differenti ...... cytomegalovirus reactivation.
@en
Expansion of highly differenti ...... cytomegalovirus reactivation.
@nl
type
label
Expansion of highly differenti ...... cytomegalovirus reactivation.
@en
Expansion of highly differenti ...... cytomegalovirus reactivation.
@nl
prefLabel
Expansion of highly differenti ...... cytomegalovirus reactivation.
@en
Expansion of highly differenti ...... cytomegalovirus reactivation.
@nl
P2093
P2860
P50
P356
P1433
P1476
Expansion of highly differenti ...... h cytomegalovirus reactivation
@en
P2093
R Seggewiss
P2860
P2888
P304
P356
10.1038/LEU.2011.135
P577
2011-06-07T00:00:00Z